Regeneron's Q2 revenue, profit bolstered by higher Eylea sales in the US

Headline results for the second quarter:


$1.6 billion (in line with forecasts)



$551.4 million

Versus profit of $387.7 million

Note: All changes are versus the prior-year period unless otherwise stated

What the company said:

"Regeneron made important commercial progress in the second quarter with continued strong US sales growth for Eylea in retinal diseases and Dupixent in atopic dermatitis," commented CEO Leonard Schleifer. He added that in the second half, Regeneron anticipates US regulatory approvals for cemiplimab in advanced cutaneous squamous cell carcinoma and for Dupixent in uncontrolled asthma. "We also plan to submit regulatory applications for Dupixent in adolescent atopic dermatitis and to report Phase III results in nasal polyps," Schleifer said.

Other results:

  • Eylea revenue in the US:  $992 million, up 8 percent, falling short of consensus estimates of $1 billion
  • Eylea overall sales$1.7 billion, up 13 percent, Bayer records product sales of the drug outside the US
  • Dupixent: $209 million, with US sales up 546 percent to $181 million, Sanofi records global net product sales for Dupixent
  • Praluent: $74 million, up 61 percent, Sanofi records global net product sales for Praluent

Looking ahead:

Regeneron now anticipates full-year revenue in the range of $455 million to $485 million, narrowed from a prior estimate of $450 million to $485 million.

To read more Top Story articles, click here.